These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 38679644)

  • 1. Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes.
    Trevisan R; Conti M; Ciardullo S
    Diabetologia; 2024 Aug; 67(8):1480-1492. PubMed ID: 38679644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa.
    Rosenstock J; Juneja R; Beals JM; Moyers JS; Ilag L; McCrimmon RJ
    Endocr Rev; 2024 May; 45(3):379-413. PubMed ID: 38224978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of once-weekly versus once-daily basal insulin analogues in the treatment of type 2 diabetes mellitus: A systematic review and meta-analysis.
    Karakasis P; Patoulias D; Pamporis K; Popovic DS; Stachteas P; Bougioukas KI; Fragakis N; Rizzo M
    Diabetes Obes Metab; 2023 Dec; 25(12):3648-3661. PubMed ID: 37667676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study.
    Frias J; Chien J; Zhang Q; Chigutsa E; Landschulz W; Syring K; Wullenweber P; Haupt A; Kazda C
    Lancet Diabetes Endocrinol; 2023 Mar; 11(3):158-168. PubMed ID: 36758572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: A meta-analysis of ONWARDS phase 3 randomized controlled trials.
    Shetty S; Suvarna R
    Diabetes Obes Metab; 2024 Mar; 26(3):1069-1081. PubMed ID: 38192022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin icodec: A novel once-weekly treatment for diabetes.
    Schaffner H; Wiener J; DeLuca A; Genovese A; Deeb A; Deeb W; Sheikh-Ali M; Sutton D; Gore A; Berner J; Huston J; Goldfaden R
    Diabet Med; 2024 Jul; ():e15414. PubMed ID: 39046097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
    Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H
    Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial.
    Mathieu C; Ásbjörnsdóttir B; Bajaj HS; Lane W; Matos ALSA; Murthy S; Stachlewska K; Rosenstock J
    Lancet; 2023 Jun; 401(10392):1929-1940. PubMed ID: 37156252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological and Benefit-Risk Profile of Once-Weekly Basal Insulin Administration (Icodec): Addressing Patients' Unmet Needs and Exploring Future Applications.
    Ingrasciotta Y; Vitturi G; Trifirò G
    J Clin Med; 2024 Apr; 13(7):. PubMed ID: 38610878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial.
    Philis-Tsimikas A; Asong M; Franek E; Jia T; Rosenstock J; Stachlewska K; Watada H; Kellerer M
    Lancet Diabetes Endocrinol; 2023 Jun; 11(6):414-425. PubMed ID: 37148899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current barriers to initiating insulin therapy in individuals with type 2 diabetes.
    Galdón Sanz-Pastor A; Justel Enríquez A; Sánchez Bao A; Ampudia-Blasco FJ
    Front Endocrinol (Lausanne); 2024; 15():1366368. PubMed ID: 38559691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-weekly Insulin Icodec as Compared to Once-daily Basal Insulins: A Meta-analysis.
    Mukhopadhyay P; Chatterjee P; Pandit K; Sanyal D; Ghosh S
    Endocr Pract; 2024 Feb; 30(2):128-134. PubMed ID: 37984730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal use of once weekly icodec insulin in type-2 diabetes: An updated meta-analysis of phase-2 and phase-3 randomized controlled trials.
    Dutta D; Nagendra L; Bhat S; Mohindra R; Surana V; Misra A
    Diabetes Metab Syndr; 2023 Oct; 17(10):102877. PubMed ID: 37832481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes.
    Philis-Tsimikas A; Bajaj HS; Begtrup K; Cailleteau R; Gowda A; Lingvay I; Mathieu C; Russell-Jones D; Rosenstock J
    Diabetes Obes Metab; 2023 Feb; 25(2):331-341. PubMed ID: 36106652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
    Vos RC; van Avendonk MJ; Jansen H; Goudswaard AN; van den Donk M; Gorter K; Kerssen A; Rutten GE
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD006992. PubMed ID: 27640062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial.
    Lingvay I; Asong M; Desouza C; Gourdy P; Kar S; Vianna A; Vilsbøll T; Vinther S; Mu Y
    JAMA; 2023 Jul; 330(3):228-237. PubMed ID: 37354562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-weekly basal insulin icodec: Looking ONWARDS from pharmacology to clinical trials.
    Singh AK; Singh A; Singh R; Misra A
    Diabetes Metab Syndr; 2022 Sep; 16(9):102615. PubMed ID: 36108418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic properties of the novel basal insulin Fc (insulin efsitora alfa), an insulin fusion protein in development for once-weekly dosing for the treatment of patients with diabetes.
    Heise T; Chien J; Beals JM; Benson C; Klein O; Moyers JS; Haupt A; Pratt EJ
    Diabetes Obes Metab; 2023 Apr; 25(4):1080-1090. PubMed ID: 36541037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basal weekly insulins: the way of the future!
    Rosenstock J; Del Prato S
    Metabolism; 2022 Jan; 126():154924. PubMed ID: 34728221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial.
    Bajaj HS; Bergenstal RM; Christoffersen A; Davies MJ; Gowda A; Isendahl J; Lingvay I; Senior PA; Silver RJ; Trevisan R; Rosenstock J
    Diabetes Care; 2021 Jul; 44(7):1586-1594. PubMed ID: 33875485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.